Your email has been successfully added to our mailing list.

×
0 0 0 0 0 -0.0241813602015114 -0.0241813602015114 -0.0251889168765743
Stock impact report

Kyowa Kirin Announces FDA Approval of NOURIANZ™ (istradefylline) for Use in Parkinson’s Disease

KIRIN HLDGS CO LTD S/ADR (KNBWY) 
US:NASDAQ Investor Relations: kirinholdings.co.jp/english/ir
Company Research Source: Business Wire
First and only Adenosine A2A receptor antagonist for use in Parkinson’s Disease in the U.S. TOKYO--(BUSINESS WIRE)--Kyowa Kirin Co., Ltd., (Kyowa Kirin, TYO: 4151) announces today that the U.S. Food and Drug Administration (FDA) has granted approval for NOURIANZ™ (istradefylline) for use as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson’s disease (PD) experiencing “OFF” episodes.“We are proud that NOURIANZ is now ready to help adult patients with Parkinson’s disease in the US,” said Tomohiro Sudo, Head of Global Product Management Office of Kyowa Kirin. “We believe that NOURIANZ could be an important contributor to improve treatment outcomes. We will keep working to bring the product to patients globally.”“Kyowa Kirin has a commitment to global health and well-being by creating new value through the pursuit of advances in life sciences and technology particularly in oncology, nephrology, immunology, and the central nervous system,” said Tom Stratford, P Show less Read more
Impact Snapshot
Event Time:
KNBWY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
KNBWY alerts

from News Quantified
Opt-in for
KNBWY alerts

from News Quantified